Patients Call For EU-Level Differential Pricing
In a “strengthened call to action” to improve access to medicines, the European Patients Forum says an EU-level reflection on differential pricing is needed and that patients should to be more central to designing R&D.
You may also be interested in...
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.